NCCN Receives $2.2 Million in Research Funding from Astellas and Medivation to Study Enzalutamide in Solid Tumors
The NCCN Oncology Research Program (ORP) received a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to facilitate studies of enzalutamide in bladder, breast, endometrial, hepatocellular, ovarian, and prostate cancers.FORT WASHINGTON, PA — The National Comprehensive Cancer Network ® (NCCN ®) Oncology Research Program (ORP ) has been awarded a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to develop a